Currently, the standard treatment of breast cancer is based only on clinical and pathological features, such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)104, which is not sufficient to achieve precise individualized treatment. Here, PGR is linked to breast carcinoma.